Navigation Links
PET technique promises better detection and response assessment for Non-Hodgkin's lymphoma
Date:12/21/2011

Reston, Va. Positron emission tomography (PET) and a molecular imaging agent that captures the proliferation of cancer cells could prove to be a valuable method for imaging a form of Non-Hodgkin's disease called mantle cell lymphoma, a relatively rare and devastating blood cancer. The pilot study is published in the December issue of the Journal of Nuclear Medicine.

Lymphoma is the term used for an array of cancers that affect blood cells and the lymphatic system. These cancers are typically categorized as either Hodgkin's or non-Hodgkin's. Mantle cell lymphoma (MCL) is a type of non-Hodgkin's lymphoma that accounts for approximately 6 percent, or roughly 3,000, of lymphoma cases in America, with prevalence in male populations over 60 years of age. MCL is caused by abnormal gene expression of B-cell lymphocytes within the mantle zone of lymph nodes. Normally these cells produce antibodies involved in the body's natural immune response, but in MCL these cells divide uncontrollably and don't terminate as healthy B-cells do.

The imaging agent being evaluated is called 3′-deoxy-3′-[F-18] fluorothymidine, or 18-F FLT. The combination of radionuclide and an analog of thymidine, a naturally occurring chemical compound that helps synchronize cell cycles, could provide a powerful biomarker for MCL.

"The encouraging results of this study should usher in new trials to investigate the role of FLT-PET for therapy response assessment and post-treatment monitoring," said one of the principal scientists, Ulrich Keller. "With further research, FLT-PET could be implemented to provide highly sensitive imaging for patients with MCL."

Researchers evaluated participants of the study using a variety of conventional imaging methods. One week before scheduled treatment with immunochemotherapy patients underwent both FLT-PET and FDG PET/CT, another molecular imaging method that targets the high glucose metabolism of cancer cells. Five of these subjects had FLT-PET imaging performed again an average of about six days after the start of treatment to assess therapy response. Results showed all cancerous lesions found with more conventional imaging methods were very highly visible using FLT-PET. Correlation between areas of intense cancer proliferation and "high spots" of F-18 FLT on PET scans was performed using immunostaining, a technique that involves staining sections of tissues with antibodies in order to detect a particular biochemical process.

"MCL is still considered a non-curable disease, despite major advances in the clinical management of disease, underlining the need for reliable response assessment and post-treatment monitoring," added Keller. "The most widely used PET imaging agents have not yet proven to be beneficial for either one of them, which indicates FLT-PET's potential for MCL imaging."

Further research is expected to be conducted to confirm the efficacy of FLT-PET for initial detection and early response assessment of MCL.


'/>"/>
Contact: Rebecca Maxey
rmaxey@snm.org
703-652-6772
Society of Nuclear Medicine
Source:Eurekalert

Related medicine news :

1. Princeton technique puts chemistry breakthroughs on the fast track
2. New and varied imaging techniques facilitate personalized medicine
3. Kessler Foundation reports benefits of behavioral technique for cognitive rehabilitation in MS
4. Imaging technique IDs plaques, tangles in brains of severely depressed older adults
5. New Technique to Remove Skull Tumors May Mean Less Scarring
6. First report of increased safety using simultaneous techniques for cardiac testing published
7. New technique identifies first events in tumor development
8. Novel technique reveals both gene number and protein expression simultaneously
9. New imaging technique visualizes cancer during surgery
10. U of T research shows anti-aging techniques not yet viewed as acceptable
11. Improved radical surgery techniques provide positive outcomes for bladder cancer patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... ... August 18, 2017 , ... Alcovit, a lime-flavored beverage that rids the ... efforts with its product now available through Jet.com. , After 25 years of ... powdered drink is designed to quickly detox the body thereby avoiding alcohol-induced hangovers. Whether ...
(Date:8/18/2017)... ... , ... “Our Mountains to Climb: A Journey of Love and Faith Through ... through the faith they shared to overcome struggles in life. “Our Mountains to Climb: ... Barbara J. Corcoran, a retired teacher and happily married since 1999; the author’s personal ...
(Date:8/18/2017)... ... August 18, 2017 , ... “Beyond Our Imaginations: The Infinite ... Our Imaginations: The Infinite God” is the creation of published author, Mark Lawrence, born ... , Lawrence shares, “The problem with becoming a greater man of God is that ...
(Date:8/18/2017)... ... August 18, 2017 , ... “Kingdom Mandate for Kingdom ... Kingdom. “Kingdom Mandate for Kingdom Builders” is the creation of published author, John ... to Eastern Europe as a missionary in 1983. He spent three decades training ...
(Date:8/18/2017)... ... 18, 2017 , ... “Case #10-5411 Veterans Administration”: a personal ... “Case #10-5411 Veterans Administration” is the creation of published author, Carol Mulhern, single ... Carol Mulhem started work at the Coatesville VAMC as a file clerk then ...
Breaking Medicine News(10 mins):
(Date:8/10/2017)... , Aug. 10, 2017  Physical Rehabilitation Network (PRN), ... in Lakewood, Colorado . The reputable clinic ... Lipkin , PT, DPT with his staff of four clinicians. ... of Pittsburgh and brings over 10 years of experience with ... Belmar PT marks the 10th PRN clinic in and ...
(Date:8/8/2017)... DUBLIN, Aug. 8, 2017   ... $3.12 diluted (GAAP) loss per share from continuing operations ... Products revenues increased 16 percent to $110 million ... increased 27 percent to $161 million ... (EPS) from continuing operations increased 8 percent to $0.93 ...
(Date:8/7/2017)... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), ... Board of Directors has approved the payment of a quarterly ... The cash dividend of ... 27, 2017 to stockholders of record as of the close ... are subject to approval of the Board of Directors and ...
Breaking Medicine Technology: